Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation

Journal of Immunology

Volumn 187, Issue 8, 2011, Pages 4109-4118

  Rowswell Turner, Rachael B ^a   Harden, Jamie L ^a   Nair, Raji E ^a,b   Gu, Tao ^a,c   Kilinc, Mehmet O ^a   Egilmez, Nejat K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Urologix Inc   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; FEMALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR REGRESSION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CYCLOPHOSPHAMIDE; DRUG THERAPY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERLEUKIN-12; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 80054743183     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101136     Document Type: Article

References (37)

1. Kilinc, M. O., K. S. Aulakh, R. E. Nair, S. A. Jones, P. Alard, M. M. Kosiewicz, and N. K. Egilmez. 2006. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J. Immunol. 177: 6962-6973. (Pubitemid 44715062)
2. Nair, R. E., M. O. Kilinc, S. A. Jones, and N. K. Egilmez. 2006. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J. Immunol. 176: 7325-7334. (Pubitemid 43849033)
3. Gu, T., R. B. Rowswell-Turner, M. O. Kilinc, and N. K. Egilmez. 2010. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res. 70: 129-138.
4. Peggs, K. S., S. A. Quezada, and J. P. Allison. 2008. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev. 224: 141-165.
5. Curran, M. A., W. Montalvo, H. Yagita, and J. P. Allison. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107: 4275-4280.
6. Josefowicz, S. Z., and A. Rudensky. 2009. Control of regulatory T cell lineage commitment and maintenance. Immunity 30: 616-625.
7. Zhou, G., C. G. Drake, and H. I. Levitsky. 2006. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107: 628-636. (Pubitemid 43076387)
8. Zhou, G., and H. I. Levitsky. 2007. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 178: 2155-2162. (Pubitemid 46233413)
9. Emens, L. A., and E. M. Jaffee. 2005. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65: 8059-8064. (Pubitemid 41330564)
10. Zitvogel, L., L. Apetoh, F. Ghiringhelli, and G. Kroemer. 2008. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8: 59-73.
11. Mihich, E. 1969. Modification of tumor regression by immunologic means. Cancer Res. 29: 2345-2350.
12. van der Most, R. G., A. J. Currie, A. L. Cleaver, J. Salmons, A. K. Nowak, S. Mahendran, I. Larma, A. Prosser, B. W. S. Robinson, M. J. Smyth, et al. 2009. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS ONE 4: e6982.
13. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344. (Pubitemid 39255944)
14. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912. (Pubitemid 41396891)
15. Nowak, A. K., R. A. Lake, and B. W. S. Robinson. 2006. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv. Drug Deliv. Rev. 58: 975-990. (Pubitemid 44780907)
16. Radojcic, V., K. B. Bezak, M. Skarica, M. A. Pletneva, K. Yoshimura, R. D. Schulick, and L. Luznik. 2010. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol. Immunother. 59: 137-148.
17. Medina-Echeverz, J., J. Fioravanti, M. Zabala, N. Ardaiz, J. Prieto, and P. Berraondo. 2011. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J. Immunol. 186: 807-815.
18. Hill, H. C., T. F. Conway, Jr., M. S. Sabel, Y. S. Jong, E. Mathiowitz, R. B. Bankert, and N. K. Egilmez. 2002. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 62: 7254-7263. (Pubitemid 36025247)
19. Gu, T., M. O. Kilinc, and N. K. Egilmez. 2008. Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease. Cancer Immunol. Immunother. 57: 997-1005.
20. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
21. Amici, A., A. Smorlesi, G. Noce, G. Santoni, P. Cappelletti, L. Capparuccia, R. Coppari, R. Lucciarini, C. Petrelli, and M. Provinciali. 2000. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther. 7: 703-706. (Pubitemid 30255775)
22. Manjili, M. H., X. Y. Wang, X. Chen, T. Martin, E. A. Repasky, R. Henderson, and J. R. Subjeck. 2003. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J. Immunol. 171: 4054-4061. (Pubitemid 37238680)
23. Lustgarten, J., A. L. Dominguez, and C. Cuadros. 2004. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. 34: 752-761. (Pubitemid 39255923)
24. Wagner, S., J. Jasinska, H. Breiteneder, M. Kundi, H. Pehamberger, O. Scheiner, C. C. Zielinski, and U. Wiedermann. 2007. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res. Treat. 106: 29-38. (Pubitemid 47498086)
25. Nair, R. E., Y. S. Jong, S. A. Jones, A. Sharma, E. Mathiowitz, and N. K. Egilmez. 2006. IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J. Immunother. 29: 10-20.
26. Cailleau, C., A. Diu-Hercend, E. Ruuth, R. Westwood, and C. Carnaud. 1997. Treatment with neutralizing antibodies specific for IL-1beta prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 46: 937-940. (Pubitemid 27220991)
27. Reddy, S., and M. Young. 2002. IL-1beta expression in islet cells of the NOD mouse and its spatial relationship to beta cells and inducible nitric oxide synthase. Ann. N. Y. Acad. Sci. 958: 190-193. (Pubitemid 34592225)
28. Matsushita, N., S. A. Pilon-Thomas, L. M. Martin, and A. I. Riker. 2008. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J. Immunol. Methods 333: 167-179.
29. Reilly, R. T., M. B. C. Gottlieb, A. M. Ercolini, J.-P. H. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60: 3569-3576. (Pubitemid 30482178)
30. Machiels, J.-P. H., R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, and E. M. Jaffee. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61: 3689-3697. (Pubitemid 32694981)
31. Ercolini, A. M., B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J.-P. H. Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee. 2005. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602. (Pubitemid 40723662)
32. Wolpoe, M. E., E. R. Lutz, A. M. Ercolini, S. Murata, S. E. Ivie, E. S. Garrett, L. A. Emens, E. M. Jaffee, and R. T. Reilly. 2003. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J. Immunol. 171: 2161-2169. (Pubitemid 36966500)
33. Kilinc, M. O., T. Gu, J. L. Harden, L. P. Virtuoso, and N. K. Egilmez. 2009. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J. Immunol. 182: 4217-4225.
34. Lollini, P.-L., G. Nicoletti, L. Landuzzi, C. De Giovanni, I. Rossi, E. Di Carlo, P. Musiani, W. J. Muller, and P. Nanni. 1998. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer 77: 937-941. (Pubitemid 28378147)
35. Motoyoshi, Y., K. Kaminoda, O. Saitoh, K. Hamasaki, K. Nakao, N. Ishii, Y. Nagayama, and K. Eguchi. 2006. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol. Rep. 16: 141-146.
36. van der Most, R. G., K. Murali-Krishna, J. G. Lanier, E. J. Wherry, M. T. Puglielli, J. N. Blattman, A. Sette, and R. Ahmed. 2003. Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology 315: 93-102. (Pubitemid 37340053)
37. Klein, L., L. Trautman, S. Psarras, S. Schnell, A. Siermann, R. Liblau, H. von Boehmer, and K. Khazaie. 2003. Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur. J. Immunol. 33: 806-814. (Pubitemid 36367684)